Form 4: United Therapeutics Director Christopher Patusky Reports Stock Transactions
SEC Form 4 Filing
Director Christopher Patusky reports the acquisition and disposal of United Therapeutics Corp (UTHR) common stock on June 17, 2024.
Summary
- On June 17, 2024, Christopher Patusky, a director of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock.
- Patusky exercised stock options to acquire 2,000 shares of common stock at a price of $76.36 per share.
- Simultaneously, Patusky disposed of 2,000 shares of common stock at a price of $295.5 per share.
- Following these transactions, Patusky directly owns no shares and indirectly owns 1,100 shares through a trust.
- He also directly owns 3,000 stock options.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's future.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The information is used by investors to understand management's perspective on the value of the company.
Stakeholder Impact
- The transactions may provide insights to shareholders regarding the director's view on the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 06/26/2020 | Date stock options became exercisable |
| 06/17/2024 | Date of stock acquisition and disposal |
| 06/18/2024 | Date of signature on the report |
| 06/26/2029 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.